Last 24 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.67 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.52 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 9.78 | — | — | 1.62 | — | 6.04 | — | — | — | — | 3.38 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 2.49 | 16.84 | 2.96 | 1.34 | 2.02 | 0.78 | 0.58 | 0.78 | 1.45 | 1.18 | 1.19 | 0.64 | 0.60 | 0.68 | 0.93 | 0.29 | 0.34 | 0.36 | 0.56 | 1.33 | — |
| — | +2066.5% | +410.8% | +70.6% | +39.3% | -34.1% | -51.1% | +22.4% | +143.2% | +74.3% | +27.4% | +120.0% | +75.4% | +85.7% | +66.6% | -78.1% | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.8% | — | — | 103.9% | — | 100.0% | — | — | — | — | 97.1% | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -609.2% | — | — | -165.7% | — | -700.4% | — | — | — | — | -34.7% | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -574.5% | — | — | -164.0% | — | -650.9% | — | — | — | — | -20.2% | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -91.4% | -118.7% | -55.0% | -29.6% | -28.1% | -19.2% | -18.9% | -25.9% | -13.1% | -9.8% | -2.1% | -11.8% | -16.3% | -10.7% | -12.3% | -20.7% | -13.8% | -11.5% | -12.7% | -17.7% | — |
| — | -516.8% | -190.8% | -14.3% | -114.6% | -96.9% | -799.5% | -119.1% | +19.5% | +8.6% | +82.9% | +42.7% | -17.8% | +6.8% | +3.0% | -16.5% | — | — | +97.8% | +93.4% | — | |
| ROA | -64.0% | -42.5% | -29.9% | -18.4% | -19.2% | -14.2% | -14.4% | -20.2% | -10.5% | -8.1% | -1.7% | -8.7% | -12.7% | -8.9% | -9.8% | -16.6% | -11.9% | -10.3% | -11.8% | -8.0% | -9.9% |
| — | -200.1% | -106.9% | +9.0% | -83.1% | -75.5% | -773.6% | -133.2% | +17.5% | +9.1% | +83.1% | +47.8% | -7.3% | +14.0% | +17.1% | -106.7% | -19.9% | -86.3% | — | +82.2% | — | |
| ROIC | -71.1% | -74.0% | -36.9% | -20.5% | -20.2% | -14.3% | -14.8% | -21.2% | -10.9% | -8.8% | -2.7% | -9.4% | -13.3% | -10.5% | -26.2% | -848.4% | -403.5% | — | — | — | — |
| — | -415.7% | -148.9% | +3.4% | -86.2% | -63.5% | -454.7% | -124.4% | +18.4% | +16.1% | +89.8% | +98.9% | +96.7% | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.35 | 1.56 | 0.58 | 0.35 | 0.28 | 0.22 | 0.19 | 0.17 | 0.13 | 0.12 | 0.11 | 0.17 | 0.16 | 0.15 | 0.13 | 0.12 | 0.09 | 0.07 | — | 0.00 | — |
| — | +601.9% | +203.4% | +109.0% | +107.5% | +80.6% | +70.6% | -1.4% | -14.7% | -16.0% | -15.2% | +44.2% | +84.3% | +97.8% | — | +18545.0% | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.41 | 1.34 | 2.76 | 3.41 | 4.29 | 5.65 | 7.75 | 7.49 | 7.33 | 9.53 | 12.19 | 4.84 | 4.91 | 16.18 | 13.46 | 5.90 | 10.62 | 15.19 | 13.10 | 14.90 | 7.98 |
| — | -76.4% | -64.4% | -54.4% | -41.5% | -40.7% | -36.4% | +54.9% | +49.2% | -41.1% | -9.5% | -18.0% | -53.8% | +6.5% | +2.8% | -60.4% | +33.1% | -10.6% | — | +578.2% | — | |
| Quick Ratio | 3.41 | 1.34 | 2.76 | 3.41 | 4.29 | 5.65 | 7.75 | 7.49 | 7.33 | 9.53 | 12.19 | 4.84 | 4.91 | 16.18 | 13.46 | 5.90 | 10.62 | 15.19 | 13.10 | 14.90 | 7.98 |
| — | -76.4% | -64.4% | -54.4% | -41.5% | -40.7% | -36.4% | +54.9% | +49.2% | -41.1% | -9.5% | -18.0% | -53.8% | +6.5% | +2.8% | -60.4% | +33.1% | -10.6% | — | +578.2% | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 24 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PYXS stock.
Pyxis Oncology, Inc.'s current P/E is -1.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Pyxis Oncology, Inc.'s current operating margin is -609.2%. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Pyxis Oncology, Inc.'s business trajectory between earnings reports.